Who makes Prednisolone 1% topical eye drops?

Prednisolone 1% topical eye drops is developed by Hotel Dieu Hospital.

What development phase is Prednisolone 1% topical eye drops in?

Prednisolone 1% topical eye drops is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Prednisolone 1% topical eye drops

Hotel Dieu Hospital · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Prednisolone 1% topical eye drops
Sponsor	Hotel Dieu Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (PHASE4)
Dropless Pars Plana Vitrectomy Study (PHASE4)
Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prednisolone 1% topical eye drops CI brief — competitive landscape report
Prednisolone 1% topical eye drops updates RSS · CI watch RSS
Hotel Dieu Hospital portfolio CI